PIK3CA and acute myeloid leukemia: Recent experiments performed in acute myeloid leukemia (AML) model showed that inhibition of p110δ PI3K has also been found to enhance efficacy and memory in tumor-specific therapeutic CD8 T cells, while inhibition of p110α PI3K increased cytokine production and antitumor response [48].